other glp 1 agonists GLP-1 Receptor and Research to Treat Overeating and Substance Use Disorders Best Med #2: GLP-1 Receptor
Description
It is suspected that these benefits apply to other patient populations, although there are insufficient data to support such speculations, particularly in obese patients with AID
Despite the promising results, the glucose-responsiveness of these IPC remains limited
What was once limited to expensive in-person specialist visits is now available to anyone with an internet connection
Angulo MA, Butler MG, Cataletto ME
Candidates for Semaglutide have a BMI over 30, or over 27 with at least one related condition such as high blood pressure, high cholesterol or diabetes (Type 2)
The study found that on average, people taking semaglutide lost 14.9% of their starting body weight after 68 weeks (almost 1 1/2 years)
